Clinical Efficacy and Safety Analysis of 1.5% Ruxolitinib Cream in The Treatment of Facial Vitiligo in Adolescents: A Retrospective Study of 74 Cases - PubMed
3 hours ago
- #Adolescent Vitiligo
- #Ruxolitinib
- #Facial Vitiligo Treatment
- Study evaluates 1.5% Ruxolitinib cream for treating facial vitiligo in adolescents.
- Retrospective analysis includes 74 cases to assess clinical efficacy and safety.
- Focuses on both non-segmental and segmental vitiligo types in adolescent patients.
- Findings contribute to understanding Ruxolitinib's role in vitiligo treatment.